StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals
CADLBullishEarningsnews
High materiality9/10

Candel aims to submit BLA in 2026 as Lancet data reinforce prostate cancer potential

Aug 13, 2026, 8:08 AM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

Material regulatory milestone (Q4 2026 BLA) plus positive phase 3 data (Lancet Oncology) and a broadened trial program (AURORA) create near-term upside if milestones are met; liquidity coverage into 2028 reduces funding risk, supporting a more favorable risk/reward.

AI summary

What happened, with direct paths to the underlying reporting

Candel Therapeutics reports a strong Q2 2026 with $201.6 million in cash and a plan to submit a BLA for aglatimagene in Q4 2026. The Lancet Oncology pivotal data show a meaningful disease-free survival improvement when aglatimagene is added to radiotherapy, supporting a potential 2027 US launch if approved. The AURORA NSCLC trial is now active, expanding the platform’s reach and near-term catalysts.

  • BLA planned for aglatimagene in localized prostate cancer in Q4 2026. Regulatory milestone.
  • Lancet Oncology pivotal phase 3 data show DFS improvement with aglatimagene plus radiotherapy.
  • AUA 2026 follow-up: 745 patients; aglatimagene DFS improvement of 39%.
  • AURORA NSCLC trial first site activated; global enrollment planned.
  • Cash and equivalents $201.6M as of 6/30/2026; runway into Q1 2028.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Related signals

More source-backed signals connected by company or event